Pharmacokinetics of new nootropic acylprolyldipeptide and its penetration across the blood-brain barrier after oral administration

Bull Exp Biol Med. 2000 Apr;129(4):359-61. doi: 10.1007/BF02439270.


Pharmacokinetics of GVS-111, a new acylprolyldipeptide with nootropic properties and its penetration across the blood-brain barrier were studied in rats using HPLC. It was found that the dipeptide is absorbed in the gastrointestinal tract, enters the circulation, and penetrates through the blood-brain barrier in an unmodified state.

MeSH terms

  • Administration, Oral
  • Animals
  • Blood-Brain Barrier / drug effects*
  • Dipeptides / administration & dosage
  • Dipeptides / pharmacokinetics*
  • Male
  • Nootropic Agents / administration & dosage
  • Nootropic Agents / pharmacokinetics*
  • Rats


  • Dipeptides
  • Nootropic Agents
  • ethyl phenylacetyl-Pro-Gly